vs
亚盛医药集团（AAPG）与艾伯维（ABBV）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是亚盛医药集团的28945.2倍（$16.6B vs $574.1K）
亚盛医药集团是一家全球性临床阶段生物技术企业，专注于开发用于治疗癌症、慢性病毒感染及衰老相关疾病的创新靶向药物，核心研发方向为靶向细胞凋亡通路的小分子药物，业务覆盖中、美等全球市场，致力于满足未被满足的临床需求。
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
AAPG vs ABBV — 直观对比
营收规模更大
ABBV
是对方的28945.2倍
$574.1K
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $574.1K | $16.6B |
| 净利润 | — | $1.8B |
| 毛利率 | — | 72.6% |
| 营业利润率 | — | 27.3% |
| 净利率 | — | 10.9% |
| 营收同比 | — | 10.0% |
| 净利润同比 | — | 8354.5% |
| 每股收益（稀释后） | — | $1.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAPGABBV
| Q4 25 | $574.1K | $16.6B | ||
| Q3 25 | — | $15.8B | ||
| Q2 25 | $32.6M | $15.4B | ||
| Q1 25 | — | $13.3B | ||
| Q4 24 | — | $15.1B | ||
| Q3 24 | — | $14.5B | ||
| Q2 24 | — | $14.5B | ||
| Q1 24 | — | $12.3B |
净利润AAPGABBV
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $186.0M | ||
| Q2 25 | $11.4M | $938.0M | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $-22.0M | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
毛利率AAPGABBV
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 66.4% | ||
| Q2 25 | 90.7% | 71.8% | ||
| Q1 25 | — | 70.0% | ||
| Q4 24 | — | 70.9% | ||
| Q3 24 | — | 70.9% | ||
| Q2 24 | — | 70.9% | ||
| Q1 24 | — | 66.7% |
营业利润率AAPGABBV
| Q4 25 | — | 27.3% | ||
| Q3 25 | — | 12.1% | ||
| Q2 25 | — | 31.7% | ||
| Q1 25 | — | 28.0% | ||
| Q4 24 | — | -9.9% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | 22.7% |
净利率AAPGABBV
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 9.6% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 9.5% | ||
| Q1 24 | — | 11.1% |
每股收益（稀释后）AAPGABBV
| Q4 25 | — | $1.02 | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | — | $0.52 | ||
| Q1 25 | — | $0.72 | ||
| Q4 24 | — | $-0.03 | ||
| Q3 24 | — | $0.88 | ||
| Q2 24 | — | $0.77 | ||
| Q1 24 | — | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $5.3B |
| 总债务越低越好 | — | $58.9B |
| 股东权益账面价值 | — | $-3.3B |
| 总资产 | — | $134.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AAPGABBV
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $5.7B | ||
| Q2 25 | — | $6.5B | ||
| Q1 25 | — | $5.2B | ||
| Q4 24 | — | $5.6B | ||
| Q3 24 | — | $7.3B | ||
| Q2 24 | — | $13.2B | ||
| Q1 24 | — | $18.1B |
总债务AAPGABBV
| Q4 25 | — | $58.9B | ||
| Q3 25 | — | $63.0B | ||
| Q2 25 | — | $63.0B | ||
| Q1 25 | — | $64.5B | ||
| Q4 24 | — | $60.3B | ||
| Q3 24 | — | $58.5B | ||
| Q2 24 | — | $58.0B | ||
| Q1 24 | — | $63.8B |
股东权益AAPGABBV
| Q4 25 | — | $-3.3B | ||
| Q3 25 | — | $-2.6B | ||
| Q2 25 | — | $-183.0M | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $6.0B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $8.0B |
总资产AAPGABBV
| Q4 25 | — | $134.0B | ||
| Q3 25 | — | $133.9B | ||
| Q2 25 | — | $137.2B | ||
| Q1 25 | — | $136.2B | ||
| Q4 24 | — | $135.2B | ||
| Q3 24 | — | $143.4B | ||
| Q2 24 | — | $141.9B | ||
| Q1 24 | — | $148.9B |
负债/权益比AAPGABBV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 45.44× | ||
| Q4 24 | — | 18.15× | ||
| Q3 24 | — | 9.70× | ||
| Q2 24 | — | 8.56× | ||
| Q1 24 | — | 7.97× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $5.2B |
| 自由现金流经营现金流 - 资本支出 | — | $4.9B |
| 自由现金流率自由现金流/营收 | — | 29.4% |
| 资本支出强度资本支出/营收 | — | 2.0% |
| 现金转化率经营现金流/净利润 | — | 2.87× |
| 过去12个月自由现金流最近4个季度 | — | $17.8B |
8季度趋势，按日历期对齐
经营现金流AAPGABBV
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $7.0B | ||
| Q2 25 | — | $5.2B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $7.0B | ||
| Q3 24 | — | $5.4B | ||
| Q2 24 | — | $2.3B | ||
| Q1 24 | — | $4.0B |
自由现金流AAPGABBV
| Q4 25 | — | $4.9B | ||
| Q3 25 | — | $6.6B | ||
| Q2 25 | — | $4.9B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $6.8B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $3.8B |
自由现金流率AAPGABBV
| Q4 25 | — | 29.4% | ||
| Q3 25 | — | 42.1% | ||
| Q2 25 | — | 31.7% | ||
| Q1 25 | — | 10.5% | ||
| Q4 24 | — | 44.7% | ||
| Q3 24 | — | 35.9% | ||
| Q2 24 | — | 14.0% | ||
| Q1 24 | — | 31.3% |
资本支出强度AAPGABBV
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 2.4% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | 1.6% |
现金转化率AAPGABBV
| Q4 25 | — | 2.87× | ||
| Q3 25 | — | 37.76× | ||
| Q2 25 | — | 5.49× | ||
| Q1 25 | — | 1.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.49× | ||
| Q2 24 | — | 1.66× | ||
| Q1 24 | — | 2.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
